PARP1 and Inherited cancer-predisposing syndrome: These elements are essential for the reliable molecular identification of BRCA CNVs, which have critical implications for the management of OC patients, including therapeutic decisions involving PARP inhibitors and cascade testing in hereditary cancer syndromes.